Abstract
Background: Bone fractures in patients on dialysis are frequent and impose a high burden of disability and multimorbidity. They have been linked to mineral-bone disorders but its association with parathyroid hormone remains controversial.
Purpose: To determine the relationship between altered parathyroid hormone (PTH) and bone fractures in hemodialysis patients.
Metthodology: A cross-sectional, analytical study was conducted in 250 hemodialysis patients attending Hospital Víctor Lazarte Echegaray from 2015 to 2020. Patients were classified according to whether their PTH was altered (PTH <150 or >300 pg/ml) and whether bone fractures were present. The association between altered PTH and the presence of bone fractures was determined using bivariate and multivariate analysis; the results are presented as odds ratio (OR) considering a significant p-value if <0.05.
Results: 250 patients were evaluated in which 69 (27.6%) had altered PTH, 181 (72.4%) had normal PTH; likewise, 42 (16.8%) had bone fractures and 208 (83.2%) had no bone fractures. Of the 42 patients with bone fractures, 22 (52.4%) had altered PTH and 20 (47.6%) had normal PTH; of the 208 patients without bone fractures, 47 (22.6%) had altered PTH and 161 (77.4%) had normal PTH (p=0.001). Altered PTH was associated with the presence of bone fractures with OR: 3.77 (95% CI: 1.90-7.49) in the bivariate analysis and with OR: 2.85 (95% CI: 1.19-6.82) in the multivariate analysis. The covariates that were associated with the presence of bone fractures were being over 60 years (OR: 2.74, 95% CI: 1.12-6.69) and having been on hemodialysis for more than 5 years (OR: 6.72, 95% CI: 2.98-15.13).
Conclusions: Altered parathyroid hormone is related with bone fractures in hemodialysis patients.
References
Wu AM, Bisignano C, James SL, Abady GG, Abedi A, Abu-Gharbieh E, et al. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021;2(9):e580-92. https://doi.org/10.1016/S2666-7568(21)00172-0
Li N, van Oostwaard M, van den Bergh JP, Hiligsmann M, Boonen A, van Kuijk SM, et al. Health-related quality of life of patients with a recent fracture attending a fracture liaison service: a 3-year follow-up study. Osteoporos Int. 2022;33(3):577-88. https://doi.org/10.1007/s00198-021-06204-x
Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014;85(1):166-73. https://doi.org/10.1038/ki.2013.279
Ambrus C, Almasi C, Berta K, Deak G, Marton A, Molnar M, et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol. 2010;43(2):475-82. https://doi.org/10.1007/s11255-010-9723-x
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358-66. https://doi.org/10.1038/sj.ki.5001754
Arboleya L. Trastorno mineral y óseo asociado a la enfermedad renal crónica. Reumatol Clín. 2011;7(supl. 2):18-21. https://doi.org/10.1016/j.reuma.2011.05.006
Torregrosa JV, Bover J, Rodríguez Portillo M, González Parra E, Arenas MD, Caravaca F, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica: 2021 (SEN-MM). Nefrología. 2022;42(supl. 3):1-36. https://doi.org/10.1016/j.nefro.2022.03.007
Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. Nephrology. 2018;23:88-94. https://doi.org/10.1111/nep.13457
Bernuy J, Gonzales GF. Metabolismo mineral óseo en pacientes con enfermedad renal crónica: revisión sobre su fisiopatología y morbimortalidad. Rev Peru Med Exp Salud Pública. 2015;32(2):326-34. https://doi.org/10.17843/rpmesp.2015.322.1628
Desmet C, Beguin C, Swine C, Jadoul M. Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications. Am J Kidney Dis. 2005;45(1):148-53. https://doi.org/10.1053/j.ajkd.2004.09.027
Roberts RG, Anne Kenny R, Brierley EJ. Are elderly haemodialysis patients at risk of falls and postural hypotension? Int Urol Nephrol. 2003;35(3):415-21. https://doi.org/10.1023/b:urol.0000022866.07751.4a
Hansen D, Olesen J, Gislason G, Abrahamsen B, Hommel K. Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. Nephrol Dial Transplant. 2016;31(10):1654-62. https://doi.org/10.1093/ndt/gfw073
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115-21. https://doi.org/10.1053/ajkd.2000.19812
Fishbane S, Hazzan A, Jhaveri K, Ma L, Lacson E. Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2016;11(6):1063-72. https://doi.org/10.2215/cjn.09280915
Matias PJ, Laranjinha I, Azevedo A, Raimundo A, Navarro D, Jorge C, et al. Bone fracture risk factors in prevalent hemodialysis patients. J Bone Miner Metab. 2020;38(2):205-12. https://doi.org/10.1007/s00774-019-01041-9
Arenas MD. Alteraciones del Metabolismo Mineral: Calcio, Fósforo, PTH, Vitamina D, FGF-23, Klotho. Nefrol día. 2020:55.
Hruska KA, Seifert M. Pathophysiology of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). En: Rosen CJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8ª ed. Estados Unidos: John Wiley & Sons; 2013. p. 632-9. https://doi.org/10.1002/9781118453926.ch77
Alshayeb HM, Quarles LD. Treatment Of Chronic Kidney Disease Mineral Bone Disorder (CKD–MBD). En: Rosen CJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8ª ed. Estados Unidos: John Wiley & Sons; 2013. p. 640-50. https://doi.org/10.1002/9781118453926.ch78
Bover J, Arana C, Ureña P, Torres A, Martín-Malo A, Fayos L, et al. Hiporrespuesta o resistencia a la acción de la hormona paratiroidea en la enfermedad renal crónica. Nefrología. 2021;41(5):514-28. https://doi.org/10.1016/j.nefro.2020.12.019
Haarhaus M, Evenepoel P. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 2021;100(3):546-58. https://doi.org/10.1016/j.kint.2021.04.043
Lloret MJ, Bover J, DaSilva I, Furlano M, Ruiz-García C, Ayasreh N, et al. Papel del fósforo en la enfermedad renal crónica. Nefrología Sup Ext. 2013;4(2):2-10. https://www.revistanefrologia.com/es-papel-del-fosforo-enfermedad-renal-articulo-X2013757513003136
Mathew AT, Hazzan A, Jhaveri KD, Block GA, Chidella S, Rosen L, et al. Increasing Hip Fractures in Patients Receiving Hemodialysis and Peritoneal Dialysis. Am J Nephrol. 2014;40(5):451-7. https://doi.org/10.1159/000369039
Portal-Núñez S, Lozano D, de la Fuente M, Esbrit P. Fisiopatología del envejecimiento óseo. Rev Esp Geriatría Gerontol. 2012;47(3):125-31. https://doi.org/10.1016/j.regg.2011.09.003
Teruel-Briones JL, Fernández-Lucas M, Rivera-Gorrin M, Ruiz-Roso G, Diaz-Domínguez M, Rodríguez-Mendiola N, et al. Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis. Nephrology. 2013;33(5):640-9.
Chen YJ, Kung PT, Wang YH, Huang CC, Hsu SC, Tsai WC, et al. Greater risk of hip fracture in hemodialysis than in peritoneal dialysis. Osteoporos Int. 2014;25(5):1513-8. https://doi.org/10.1007/s00198-014-2632-6
Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y. Increased Incidence of Vertebral Fracture in Older Female Hemodialyzed Patients with Type 2 Diabetes Mellitus. Calcif Tissue Int. 2005;76(4):256-60. https://doi.org/10.1007/s00223-004-0094-0
Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis. 2002;39(6):1261-9. https://doi.org/10.1053/ajkd.2002.33400
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.